Trader’s Buzzers: Juno Therapeutics Inc. (NASDAQ:JUNO), Tidewater Inc. (NYSE:TDW)

stock recommendation

Juno Therapeutics Inc. (NASDAQ:JUNO)

The company announced its last quarter financial performance results on 11/09/2016. Juno Therapeutics Inc. (NASDAQ:JUNO) belongs to Medical sector that surged 0.52% in value when last trading session closed at $19.47. The company has a market capitalization of $1.91 Billion. The company’s stock has a Return on Assets (ROA) of -19 percent, a Return on Equity (ROE) of -24 percent and Return on Investment (ROI) of -20.3 percent. The company reached its 52-Week high of $49.72 on Jun 6, 2016 and 52-Week low of $17.52 on Dec 22, 2016.

Earnings per share (ttm) for Juno Therapeutics Inc. (NASDAQ:JUNO) according to Finviz Data is $-2.81.

This company was Downgrade by Raymond James on 6-Dec-16  to Mkt Perform.

The 11 analysts offering 12-month price forecasts for Juno Therapeutics Inc have a median target of 34.00, with a high estimate of 41.00 and a low estimate of 24.00. The median estimate represents a +74.63% increase from the last price of 19.47.

Financial History:

Following Earnings result, share price were UP 4 times out of last 7 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 25% percent of times. It has met expectations  2  times and missed earnings  4  times.

The consensus recommendation for Juno Therapeutics Inc. (NASDAQ:JUNO) is 2.33. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2.3. In comparison, the consensus recommendation 60 days ago was at 1.78, and 90 days ago was at 1.63 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Juno Therapeutics Inc. to have earnings per share of $-0.63.

Revenue is expected to range from 7.5 Million to 20.3 Million with an average of 13.96 Million.

Company Profile:

Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.

Tidewater Inc. (NYSE:TDW):

Tidewater Inc. (NYSE:TDW) belongs to Transportation sector closed its last session with a gain of 1.98 percent and closed its previous trading session at $3.61. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-7.84. The company has the Market capitalization of $177.65 Million. The company’s stock has a Return on Assets (ROA) of -7.8 percent, a Return on Equity (ROE) of -16.5 percent and Return on Investment (ROI) of -2.1 percent. The company reached its 52-Week high of $11.58 on Mar 7, 2016 and 52-Week low of $1.44 on Nov 8, 2016.

The growth estimate for Tidewater Inc. (NYSE:TDW) for the current quarter is -452.4 percent. The projected growth estimate for the next quarter is -108.6 percent. The company’s stock has grown by 1.63 percent in the past 5 years. For the next 5 years, the company is expected to grow by 5 percent.

This company was Downgrade by Argus on 25-Oct-16 to Sell.

The 4 analysts offering 12-month price forecasts for Tidewater Inc have a median target of 1.75, with a high estimate of 3.00 and a low estimate of 1.00. The median estimate represents a -51.52% decrease from the last price of 3.61.

Financial History:

Following Earnings result, share price were DOWN 17 times out of last 26 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 58% percent of times. It has met expectations  1 times and missed earnings  4  times.

The consensus recommendation for Tidewater Inc. (NYSE:TDW) is 3.47. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 3.47. In comparison, the consensus recommendation 60 days ago was at 3.47, and 90 days ago was at 3.3 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Tidewater Inc. to have earnings per share of $-1.16.

Revenue is expected to range from 126.8 Million to 154.9 Million with an average of 139.13 Million.

Company Profile:

Tidewater, Inc. owns and operates one of the world’s largest fleets serving the international offshore energy industry. Tidewater vessels can be found in virtually every area of the world where there is significant oil and gas exploration, development or production. These provide a wide range of services including: transporting crews and supplies between the mainland and offshore locations; towing and positioning mobile drilling rigs; assisting in offshore construction projects; and a variety of specialized services including cable laying and 3-D seismic work.

You may missed